Activity of Fully Deleted Helper-Virus Independent Adenoviral Gene Therapy Vector
Activity of Fully Deleted Helper-Virus Independent Adenoviral Gene Therapy Vector
批准号:
8016076
负责人:
Miles Burke Brennan
金额:
$20.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-02-01 至 2012-01-31
关键词:
A-factor (Streptomyces)Adenovirus VectorAdenovirusesAnimal ModelAnimalsAntigensArchitectureBackBiologyCD8B1 geneCapsidCellsClinicalComplexDefectDevelopmentDiseaseEnzymesGene ExpressionGene Transduction AgentGenesGoalsHelper VirusesHemophilia AHepatocyteHumanHuman GenomeImmuneImmune responseImmunityImmunosuppressionInterphase CellLeadLearningLengthMediatingMusOncogenicOrnithine carbamoyltransferase deficiencyPatientsPreparationPrincipal InvestigatorProductionProteinsReagentRecombinantsResearchRetroviridaeSerotypingSurfaceSystemT-LymphocyteTestingTherapeuticTherapeutic EffectTimeTissuesTransgenesTreatment EfficacyViralViral GenesViral VectorVirusVirus Replicationbasecell typedesigneffective therapygene repairgene therapygene transfer vectorgenetically engineered virushuman F8 proteinimmunogenicimmunogenicityin vivoinnovationmouse modelnovelparticlepre-clinicalpublic health relevancerepairedsuccessvector
中文摘要
描述(由申请人提供):许多疾病是由基因缺陷引起的。基因治疗的目的是通过导入正常基因或修复基因缺陷来有效治疗或治愈这些疾病。大量的研究工作已经开始优化主要基于腺病毒和逆转录病毒的基因转移载体。然而,基因治疗的最初希望已经被常用的病毒载体的生物学破坏:逆转录病毒在整合到人类基因组中时具有内在的致突变性和致癌性;来自腺病毒的载体诱导强烈的体液和细胞免疫应答,从而否定了治疗的成功。Isogenis正在采取双管齐下的方法来解决腺病毒载体的免疫原性问题。首先,其他人也已经表明,缺失病毒基因的腺病毒载体,即完全缺失(fd,无肠)的腺病毒载体比含有更多病毒基因的载体具有更低的免疫原性。尽管深入研究,fd腺病毒载体的有效生产仍然需要使用“辅助”病毒来递送关键的腺病毒基因。Isogenis从与FDA(细胞和基因治疗部副主任Stephanie Simek博士)的讨论中了解到,使用“辅助”病毒生产fd腺病毒载体被认为是有问题的,因为目前的纯化系统不能提供“辅助”病毒污染水平低于1/3 x 1010颗粒的制剂。Isogenis已经产生了一种新的fd腺病毒载体生产系统,该系统避免了使用“辅助”病毒和复制高效重组体。Isogenis将使用这种新的载体结构来生产临床基因治疗载体,用于治疗血友病A和鸟氨酸转氨甲酰酶缺乏症(OTCD)。将在临床前动物模型中测试这些载体的活性。其次,为了克服任何剩余的免疫原性,Isogenis开发了创新的免疫抑制基因转移载体。这些采用高度特异性,但有效的免疫抑制的天然“否决”免疫抑制现象。简言之,在其表面上表达CD 8的细胞对响应于其表面上的其它抗原的T细胞施加“否决”。将在临床前动物模型中测试这些载体的活性。这些新的腺病毒载体的开发是使基因治疗回到正轨的重要一步。
公共卫生相关性:基因治疗的目标是通过引入或修复有缺陷的基因来治愈疾病。在血友病A和OTCD的情况下,“缺失”的酶将直接递送至驻留肝细胞。基因治疗载体必须在其靶组织中持续表达基因,以提供永久性治疗。针对载体蛋白的免疫应答通常否定任何治疗效果。因此,正在寻求允许生产不再含有载体衍生的(即病毒)基因的有效基因治疗载体的策略。在腺病毒载体的情况下,已经设计了这种完全缺失的载体。高效生产依赖于辅助病毒的使用。然而,使用辅助病毒被FDA认为是有问题的。目前的纯化系统不能输送辅助病毒污染水平低于1/3x 1010的制剂。因此,在本申请中,我们提出研究一组新的辅助病毒独立的完全缺失的腺病毒基因转移载体如何在体内发挥作用。
英文摘要
DESCRIPTION (provided by applicant): Numerous diseases are caused by gene defects. The goal of gene therapy is the effective treatment or cure of these diseases by the introduction of the normal gene or repair of the gene defect. A large research effort has been mounted to optimize gene transfer vectors mostly based on adenoviruses and retroviruses. Yet, the initial promise of gene therapy has been undermined by the biology of the commonly used viral vectors: retroviruses are intrinsically mutagenic and oncogenic as they integrate into the human genome; vectors derived from adenoviruses induce vigorous humoral and cellular immune responses that negate the therapeutic success. Isogenis is taking a two pronged approach to the problem of immunogenicity in Adenoviral vectors. First, others have also shown that Adenoviral vectors deleted of viral genes, i.e. fully deleted (fd, gutless) are less immunogenic than vectors containing more viral genes. Despite intensive research, the efficient production of fd Adenoviral vectors still requires the use of 'helper' viruses to deliver crucial Adenoviral genes. Isogenis had learned from its discussion with the FDA (Dr. Stephanie Simek, Deputy Director, Division of Cellular and Gene Therapy) that the use of 'helper' viruses for the production of fd Adenoviral vectors was considered problematic as present purification systems did not deliver preparations with 'helper' virus contamination levels of less than 1-in-3 x 1010 particles. Isogenis has produced a novel fd Adenoviral vector production system that avoids the use of a 'helper' virus and replication-efficient recombinants. Isogenis will use this novel vector architecture to produce clinical gene therapy vectors for the treatment of hemophilia A and ornithine transcarbamylase deficiency (OTCD). The activity of these vectors will be tested in pre-clinical animal models. Second, to overcome any remaining immunogenicity, Isogenis has developed innovative immune inhibitory gene transfer vectors. These employ the highly specific, yet effective immune suppression of the natural "veto" immune inhibitory phenomenon. Briefly, cells expressing CD8 on their surface exert a "veto" on T-cells responding to other antigens on their surface. The activity of these vectors will be tested in pre-clinical animal models. The development of these new Adenoviral vectors is a major step forward in getting gene therapy back on track.
PUBLIC HEALTH RELEVANCE: The goal of gene therapy is the cure of the disease by the introduction or repair of the defective gene. In the case of hemophilia A and OTCD, the 'missing' enzyme will be directly delivered to the resident hepatocytes. Gene therapy vectors will have to lead to sustained gene expression in their target tissue to provide a permanent cure. Immune responses directed against vector proteins generally negate any therapeutic effect. Therefore, strategies are being sought that allowed the production of effective gene therapy vectors that did no longer contain vector-derived, i.e. viral, genes. In the case of adenoviral vectors such fully deleted vectors had been designed. There efficient production depended on the use of helper viruses. Yet, the use of a helper virus was considered problematic by the FDA. Present purification systems do not deliver preparations with helper virus contamination levels of less than 1-in-3x1010. In this application, we therefore propose to investigate how w novel set of helper-virus independent fully deleted Adenoviral gene transfer vectors function in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Post-exposure immunotherapy for ricin exposure
-
批准号:10226654
-
项目类别:
-
资助金额:$79.64万
-
财政年份:2018
-
负责人:Miles Burke Brennan
-
依托单位:
Activity of Fully Deleted Helper-Virus Independent Adenoviral Gene Therapy Vector
-
批准号:7908443
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2010
-
负责人:Miles Burke Brennan
-
依托单位:
海外基金